Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
"Janssen, ASTRAZENECA LIMITED, BEIGENE NZ UNLIMITED",Bruton tyrosine kinase inhibitor (BTKi),"Chronic lymphocytic leukaemia, (CLL) without TP53 mutation, relapsed or refractory or experienced intolerable side effects to venetoclax plus rituximab",Bruton tyrosine kinase inhibitor (BTKi) (Imbruvica),Recommended for decline,Community,
